Novozymes A/S (OTCMKTS:NVZMY) Short Interest Update

Novozymes A/S (OTCMKTS:NVZMY) saw a large increase in short interest during the month of May. As of May 15th, there was short interest totaling 30,830 shares, an increase of 253.0% from the April 30th total of 8,733 shares. Based on an average daily volume of 92,688 shares, the short-interest ratio is presently 0.3 days. Currently, 0.0% of the company’s stock are short sold.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Zacks Research lowered Novozymes A/S from a “hold” rating to a “strong sell” rating in a report on Monday, May 4th. Kepler Capital Markets raised Novozymes A/S from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Finally, Rothschild & Co Redburn raised Novozymes A/S to a “strong-buy” rating in a report on Friday, March 27th. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy”.

Novozymes A/S Stock Performance

Shares of NVZMY traded down $1.41 during mid-day trading on Friday, hitting $57.61. 29,327 shares of the company’s stock were exchanged, compared to its average volume of 88,964. The company has a current ratio of 0.72, a quick ratio of 0.44 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $23.88 billion, a P/E ratio of 38.93, a P/E/G ratio of 1.10 and a beta of 0.98. Novozymes A/S has a fifty-two week low of $49.90 and a fifty-two week high of $75.99. The business’s 50 day moving average is $59.08 and its two-hundred day moving average is $60.81.

Novozymes A/S (OTCMKTS:NVZMY) last announced its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.51 EPS for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.31). The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.32 billion. Novozymes A/S had a net margin of 14.22% and a return on equity of 6.57%. On average, equities analysts expect that Novozymes A/S will post 2.43 earnings per share for the current year.

About Novozymes A/S

Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.

The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).